Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CP-101 by Finch Therapeutics Group for Ulcerative Colitis: Likelihood of Approval
CP-101 is under clinical development by Finch Therapeutics Group and currently in Phase I for Ulcerative Colitis. According to GlobalData,...